Follistatin 344 vs Bronchogen
Side-by-side comparison of key properties, dosing, and research.
Anabolic & IGF
Follistatin 344Anti-Aging & Longevity
Bronchogen- Summary
- Follistatin 344 is a recombinant form of the endogenous follistatin protein. It inhibits myostatin and activin — the primary negative regulators of muscle growth — potentially removing the genetic ceiling on muscle development. It is one of the most theoretically powerful anabolic compounds but is experimental with limited human data.
- Bronchogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is a tissue-specific bioregulator designed for the bronchi and lungs, promoting normalization of bronchial epithelial cell function. Research suggests benefits for respiratory health, protection against pulmonary aging, and support for bronchopulmonary conditions.
- Half-Life
- ~24–36 hours
- Short (minutes to hours); bioregulator effects are gene-mediated and longer lasting
- Admin Route
- SubQ, IM
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 100 mcg
- 10 mg per day
- Frequency
- Once daily
- Daily for 10–30 days
- Key Benefits
- Inhibits myostatin — removes muscle growth ceiling
- Significant increases in muscle mass and strength
- Reduces fat mass
- Promotes bone density
- May stimulate hair follicle cycling
- Anti-fibrotic effects in muscle tissue
- Synergistic with IGF-1 and other anabolic peptides
- Tissue-specific support for bronchial and lung health
- Promotes normalization of bronchial epithelial cell function
- Potential benefits in chronic bronchitis and COPD support
- Anti-aging effects on pulmonary tissue
- May reduce frequency of respiratory infections
- Supports lung function preservation with aging
- Compatible with other Khavinson bioregulator peptides
- Side Effects
- Muscle soreness (from rapid hypertrophy)
- Potential reproductive effects (activin inhibition)
- Unknown long-term safety profile
- Possible esophageal effects at high doses (animal data)
- Generally well tolerated in research studies
- Mild local reactions at injection site (if injected)
- No significant systemic side effects reported at standard doses
- Stacks With
- —
- —